The Metabolic Exchange: Conversations on MASLD, Obesity, Cardiometabolic Health, and Clinical Innovation

JOE GALATI
  • 3.0 (2)
  • Business

ABOUT THE METABOLIC EXCHANGEConversations on MASLD, obesity, cardiometabolic health, alcohol, and clinical innovation. The Metabolic Exchange is a podcast where liver science meets practical care. Hosted by hepatology leaders Dr. Joe Galati and Dr. Mazen Noureddin, the show explores the interconnections among metabolic disease, liver health, obesity, cardiovascular risk, alcohol-related conditions, and therapeutic innovation. MissionWe are clinicians and researchers guiding listeners through the evolving landscape of metabolic health. Each episode features deep conversations with hepatologists, endocrinologists, cardiologists, researchers, industry innovators, and patient advocates—bridging cutting-edge science and real-world clinical practice. Topics include trial design, therapeutic development, noninvasive diagnostics, and patient stories. Audience• Clinicians seeking actionable insights • Researchers designing studies • Industry leaders shaping treatments • Patient advocates and informed patients Meet Your HostsJoseph S. Galati, M.D., FAASLD, FACG• 33 years in liver disease; Medical Director, Conover Center for Liver Disease & Transplantation, Houston Methodist. • Founder, Houston Research Institute–Medical Center; extensive clinical trials experience in fatty liver, obesity, and cardiometabolic syndrome. • Media educator since 2003 with a weekly health radio program; author of Eating Yourself Sick; TED speaker on obesity. • Lives in Houston; active in community charities and entrepreneurship. Mazen Noureddin, M.D., FAASLD• International leader in NAFLD/NASH and NASH cirrhosis research; personal motivation from family history of disease. • Training: USC residency; NIH Liver Diseases Branch fellowship and MHS in Clinical Research; gastroenterology fellowship at UC San Diego. • Founding Director, Fatty Liver Program at Cedars-Sinai; Chief Scientific Officer at Summitt Clinical Research. • Led 40+ investigational studies; expert in noninvasive testing and advanced imaging. • Editorial roles, AASLD leadership, NIH reviewer, and active industry advisor and speaker. Together, Drs. Galati and Noureddin make complex metabolic science accessible and actionable—essential listening for researchers, pharmaceutical executive and drug developers, healthcare professionals and health-conscious audiences seeking a complete picture of metabolic health. Hosted on Acast. See acast.com/privacy for more information.

Episodes

  1. Aug 12

    New Therapies for MASLD-Expert Opinions

    Welcome to this week's episode of The Metabolic Exchange Podcast, where we're privileged to host part 2 of our conversation with Dr. Naim Alkhouri, one of the nation's leading experts in metabolic liver disease and NASH therapeutics. Dr. Alkhouri brings exceptional credentials to our discussion, serving as Director of the Steatotic Liver Program at Northshore Gastroenterology, Director of Research at the Clinical Research Institute of Ohio, and Chief Academic Officer at Summit Clinical Research in San Antonio. With over 300 published works and extensive experience as a Principal Investigator on numerous global NASH clinical trials, Dr. Alkhouri joins Dr. Joe Galati and Dr. Mazen Noureddin for an in-depth conversation about the rapidly evolving treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD). Fatty liver disease has emerged as one of the most significant public health challenges of our time, affecting an estimated 25-30% of the global population. What was once considered a benign condition is now recognized as a progressive disease that can lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent nomenclature change from NAFLD to MASLD reflects our growing understanding of the metabolic underpinnings of this condition, with insulin resistance, obesity, and type 2 diabetes serving as key drivers. As the obesity epidemic continues to expand, MASLD has become the leading cause of liver disease worldwide and a primary indication for liver transplantation. In today's episode, our expert panel explores the landmark FDA-approved therapies that are finally providing hope for patients with this condition, as well as the promising drugs currently in the development pipeline. Dr. Alkhouri's unique perspective, with his innovative research on biomarkers for diagnosis, and his current role in multiple pharmaceutical trials—offers listeners invaluable insights into where the field is headed. This timely discussion couldn't come at a better moment, as we stand at the threshold of a new era in treating metabolic liver disease. #Efruxifermin #Lanifibranor #Retatrutide #Survodutide #Resmetirom #Semaglutide Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests. For general inquiries, please email us at info@themetabolicmosaic.com. To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives. Your engagement helps us create content that matters to you, and we appreciate your continued support of the show. Hosted on Acast. See acast.com/privacy for more information.

  2. Aug 3

    Approved MASH Therapies and Pipeline

    Welcome to this week's episode of The Metabolic Exchange Podcast, where we're privileged to host Dr. Naim Alkhouri, one of the nation's leading experts in metabolic liver disease and NASH therapeutics. Dr. Alkhouri brings exceptional credentials to our discussion, serving as Director of the Steatotic Liver Program at Northshore Gastroenterology, Director of Research at the Clinical Research Institute of Ohio, and Chief Academic Officer at Summit Clinical Research in San Antonio. With over 300 published works and extensive experience as a Principal Investigator on numerous global NASH clinical trials, Dr. Alkhouri joins Dr. Joe Galati and Dr. Mazen Noureddin for an in-depth conversation about the rapidly evolving treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD). Fatty liver disease has emerged as one of the most significant public health challenges of our time, affecting an estimated 25-30% of the global population. What was once considered a benign condition is now recognized as a progressive disease that can lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent nomenclature change from NAFLD to MASLD reflects our growing understanding of the metabolic underpinnings of this condition, with insulin resistance, obesity, and type 2 diabetes serving as key drivers. As the obesity epidemic continues to expand, MASLD has become the leading cause of liver disease worldwide and a primary indication for liver transplantation. In today's episode, our expert panel explores the landmark FDA-approved therapies that are finally providing hope for patients with this condition, as well as the promising drugs currently in the development pipeline. Dr. Alkhouri's unique perspective, with his innovative research on biomarkers for diagnosis, and his current role in multiple pharmaceutical trials—offers listeners invaluable insights into where the field is headed. This timely discussion couldn't come at a better moment, as we stand at the threshold of a new era in treating metabolic liver disease. #Efruxifermin #Lanifibranor #Retatrutide #Survodutide #Resmetirom #Semaglutide Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests. For general inquiries, please email us at info@themetabolicmosaic.com. To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives. Your engagement helps us create content that matters to you, and we appreciate your continued support of the show. Hosted on Acast. See acast.com/privacy for more information.

    Approved MASH Therapies and Pipeline

  3. Jul 11

    Fatty Liver Explained

    Inaugural conversation with Dr. Joe Galati and Dr. Mazen Noureddin: a high-level, clinically focused primer on fatty liver disease (MASLD), metabolic syndrome, and why this constellation of conditions represents a growing public‑health threat. Both Dr. Galati and Dr. Noureddin are experts in liver disease and clinical research, bringing clinical perspective and trial experience to the discussion. Geared to clinicians, advanced practice providers, researchers, and trial designers, we unpack new terminology and diagnostic framing for fatty liver, summarize current FDA‑approved drug therapies and promising agents in the development pipeline, and explain how evolving treatments fit into clinical practice and trial design. Drs. Galati and Noureddin map the multidisciplinary “mosaic” of care—awareness and prevention, screening and diagnostics, lifestyle and metabolic management, and targeted therapeutic interventions—illustrating practical approaches for integrating these components to improve patient outcomes. Listen for actionable insights on diagnosis, treatment planning, and the future of MASLD research and therapeutics. Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests. For general inquiries, please email us at info@themetabolicmosaic.com. To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives. Your engagement helps us create content that matters to you, and we appreciate your continued support of the show. Hosted on Acast. See acast.com/privacy for more information.

  4. Jul 9

    Metabolic Mosaic Introduction

    Welcome the WorldThank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests. For general inquiries, please email us at info@themetabolicmosaic.com. To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives. Your engagement helps us create content that matters to you, and we appreciate your continued support of the show. Hosted on Acast. See acast.com/privacy for more information.

  • 4 Episodes

Ratings & Reviews

3
out of 5
2 Ratings

About

ABOUT THE METABOLIC EXCHANGEConversations on MASLD, obesity, cardiometabolic health, alcohol, and clinical innovation. The Metabolic Exchange is a podcast where liver science meets practical care. Hosted by hepatology leaders Dr. Joe Galati and Dr. Mazen Noureddin, the show explores the interconnections among metabolic disease, liver health, obesity, cardiovascular risk, alcohol-related conditions, and therapeutic innovation. MissionWe are clinicians and researchers guiding listeners through the evolving landscape of metabolic health. Each episode features deep conversations with hepatologists, endocrinologists, cardiologists, researchers, industry innovators, and patient advocates—bridging cutting-edge science and real-world clinical practice. Topics include trial design, therapeutic development, noninvasive diagnostics, and patient stories. Audience• Clinicians seeking actionable insights • Researchers designing studies • Industry leaders shaping treatments • Patient advocates and informed patients Meet Your HostsJoseph S. Galati, M.D., FAASLD, FACG• 33 years in liver disease; Medical Director, Conover Center for Liver Disease & Transplantation, Houston Methodist. • Founder, Houston Research Institute–Medical Center; extensive clinical trials experience in fatty liver, obesity, and cardiometabolic syndrome. • Media educator since 2003 with a weekly health radio program; author of Eating Yourself Sick; TED speaker on obesity. • Lives in Houston; active in community charities and entrepreneurship. Mazen Noureddin, M.D., FAASLD• International leader in NAFLD/NASH and NASH cirrhosis research; personal motivation from family history of disease. • Training: USC residency; NIH Liver Diseases Branch fellowship and MHS in Clinical Research; gastroenterology fellowship at UC San Diego. • Founding Director, Fatty Liver Program at Cedars-Sinai; Chief Scientific Officer at Summitt Clinical Research. • Led 40+ investigational studies; expert in noninvasive testing and advanced imaging. • Editorial roles, AASLD leadership, NIH reviewer, and active industry advisor and speaker. Together, Drs. Galati and Noureddin make complex metabolic science accessible and actionable—essential listening for researchers, pharmaceutical executive and drug developers, healthcare professionals and health-conscious audiences seeking a complete picture of metabolic health. Hosted on Acast. See acast.com/privacy for more information.

Information

You Might Also Like